Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Pulmonary inflammation induced by low dose particulate matter exposure in mice.

Schuliga M, Bartlett NW.

Am J Physiol Lung Cell Mol Physiol. 2019 Sep 18. doi: 10.1152/ajplung.00343.2019. [Epub ahead of print] No abstract available.

PMID:
31530166
2.

Anti-viral immunity is impaired in COPD patients with frequent exacerbations.

Singanayagam A, Loo SL, Calderazzo MA, Finney LJ, Trujillo Torralbo MB, Bakhsoliani E, Girkin J, Veerati PC, Pathinayake PS, Nichol KS, Reid AT, Footitt J, Johnston SL, Bartlett NW, Mallia P.

Am J Physiol Lung Cell Mol Physiol. 2019 Sep 12. doi: 10.1152/ajplung.00253.2019. [Epub ahead of print]

PMID:
31513433
3.

Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.

Singanayagam A, Glanville N, Cuthbertson L, Bartlett NW, Finney LJ, Turek E, Bakhsoliani E, Calderazzo MA, Trujillo-Torralbo MB, Footitt J, James PL, Fenwick P, Kemp SV, Clarke TB, Wedzicha JA, Edwards MR, Moffatt M, Cookson WO, Mallia P, Johnston SL.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaav3879. doi: 10.1126/scitranslmed.aav3879.

PMID:
31462509
4.

Retraction notice to "Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results" [Antiviral Research 142 (2017) 185-192].

Petrova NV, Emelyanova AG, Gorbunov EA, Edwards MR, Walton RP, Bartlett NW, Aniscenko J, Gogsadze L, Bakhsoliani E, Khaitov MR, Johnston SL, Tarasov SA, Epstein OI.

Antiviral Res. 2019 Apr;164:176. doi: 10.1016/j.antiviral.2019.02.010. No abstract available.

PMID:
30885298
5.

STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts.

Waters DW, Blokland KEC, Pathinayake PS, Wei L, Schuliga M, Jaffar J, Westall GP, Hansbro PM, Prele CM, Mutsaers SE, Bartlett NW, Burgess JK, Grainge CL, Knight DA.

Am J Respir Cell Mol Biol. 2019 Jul;61(1):61-73. doi: 10.1165/rcmb.2018-0328OC.

PMID:
30608861
6.

Increasing the Dimensionality of Soft Microstructures through Injection-Induced Self-Folding.

Ranzani T, Russo S, Bartlett NW, Wehner M, Wood RJ.

Adv Mater. 2018 Sep;30(38):e1802739. doi: 10.1002/adma.201802739. Epub 2018 Aug 6.

PMID:
30079470
7.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, Toussaint M, Walton RP, Finney LJ, Aniscenko J, Zhu J, Trujillo-Torralbo MB, Calderazzo MA, Grainge C, Loo SL, Veerati PC, Pathinayake PS, Nichol KS, Reid AT, James PL, Solari R, Wark PAB, Knight DA, Moffatt MF, Cookson WO, Edwards MR, Mallia P, Bartlett NW, Johnston SL.

Nat Commun. 2018 Jun 8;9(1):2229. doi: 10.1038/s41467-018-04574-1.

8.

Respiratory Viruses and Asthma.

Wark PAB, Ramsahai JM, Pathinayake P, Malik B, Bartlett NW.

Semin Respir Crit Care Med. 2018 Feb;39(1):45-55. doi: 10.1055/s-0037-1617412. Epub 2018 Feb 10. Review.

PMID:
29427985
9.

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches.

Reid AT, Veerati PC, Gosens R, Bartlett NW, Wark PA, Grainge CL, Stick SM, Kicic A, Moheimani F, Hansbro PM, Knight DA.

Pharmacol Ther. 2018 May;185:155-169. doi: 10.1016/j.pharmthera.2017.12.009. Epub 2017 Dec 27. Review.

PMID:
29287707
10.

Plasmacytoid dendritic cells drive acute asthma exacerbations.

Chairakaki AD, Saridaki MI, Pyrillou K, Mouratis MA, Koltsida O, Walton RP, Bartlett NW, Stavropoulos A, Boon L, Rovina N, Papadopoulos NG, Johnston SL, Andreakos E.

J Allergy Clin Immunol. 2018 Aug;142(2):542-556.e12. doi: 10.1016/j.jaci.2017.08.032. Epub 2017 Oct 17.

11.

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

Toussaint M, Jackson DJ, Swieboda D, Guedán A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Bartlett NW, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL.

Nat Med. 2017 Jun;23(6):681-691. doi: 10.1038/nm.4332. Epub 2017 May 1. Erratum in: Nat Med. 2017 Nov 7;23 (11):1384.

12.

Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.

Petrova NV, Emelyanova AG, Gorbunov EA, Edwards MR, Walton RP, Bartlett NW, Aniscenko J, Gogsadze L, Bakhsoliani E, Khaitov MR, Johnston SL, Tarasov SA, Epstein OI.

Antiviral Res. 2017 Jun;142:185-192. doi: 10.1016/j.antiviral.2017.03.017. Epub 2017 Mar 27. Retraction in: Antiviral Res. 2019 Apr;164:176.

13.

Advances in the treatment of virus-induced asthma.

Tay H, Wark PA, Bartlett NW.

Expert Rev Respir Med. 2016 Jun;10(6):629-41. doi: 10.1080/17476348.2016.1180249. Epub 2016 May 3. Review.

PMID:
27088397
14.

SOFT ROBOTICS. A 3D-printed, functionally graded soft robot powered by combustion.

Bartlett NW, Tolley MT, Overvelde JT, Weaver JC, Mosadegh B, Bertoldi K, Whitesides GM, Wood RJ.

Science. 2015 Jul 10;349(6244):161-5. doi: 10.1126/science.aab0129.

15.

Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia.

Hatchwell L, Collison A, Girkin J, Parsons K, Li J, Zhang J, Phipps S, Knight D, Bartlett NW, Johnston SL, Foster PS, Wark PA, Mattes J.

Thorax. 2015 Sep;70(9):854-61. doi: 10.1136/thoraxjnl-2014-205465. Epub 2015 Jun 24.

16.

A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD.

Singanayagam A, Glanville N, Walton RP, Aniscenko J, Pearson RM, Pinkerton JW, Horvat JC, Hansbro PM, Bartlett NW, Johnston SL.

Clin Sci (Lond). 2015 Aug;129(3):245-58. doi: 10.1042/CS20140654.

17.

The influence of asthma control on the severity of virus-induced asthma exacerbations.

Jackson DJ, Trujillo-Torralbo MB, del-Rosario J, Bartlett NW, Edwards MR, Mallia P, Walton RP, Johnston SL.

J Allergy Clin Immunol. 2015 Aug;136(2):497-500.e3. doi: 10.1016/j.jaci.2015.01.028. Epub 2015 Mar 13. No abstract available.

18.

IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo.

Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL.

Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82. doi: 10.1164/rccm.201406-1039OC.

19.

Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation.

Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M, Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW.

Sci Transl Med. 2014 Oct 1;6(256):256ra134. doi: 10.1126/scitranslmed.3009124.

20.

Mouse models of rhinovirus infection and airways disease.

Bartlett NW, Singanayagam A, Johnston SL.

Methods Mol Biol. 2015;1221:181-8. doi: 10.1007/978-1-4939-1571-2_14.

PMID:
25261315
21.

IL-15 complexes induce NK- and T-cell responses independent of type I IFN signaling during rhinovirus infection.

Jayaraman A, Jackson DJ, Message SD, Pearson RM, Aniscenko J, Caramori G, Mallia P, Papi A, Shamji B, Edwards M, Westwick J, Hansel T, Stanciu LA, Johnston SL, Bartlett NW.

Mucosal Immunol. 2014 Sep;7(5):1151-64. doi: 10.1038/mi.2014.2. Epub 2014 Jan 29.

22.

Reprogramming of lysosomal gene expression by interleukin-4 and Stat6.

Brignull LM, Czimmerer Z, Saidi H, Daniel B, Villela I, Bartlett NW, Johnston SL, Meira LB, Nagy L, Nohturfft A.

BMC Genomics. 2013 Dec 5;14:853. doi: 10.1186/1471-2164-14-853.

23.

Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma.

Mahmutovic-Persson I, Akbarshahi H, Bartlett NW, Glanville N, Johnston SL, Brandelius A, Uller L.

Allergy. 2014 Mar;69(3):348-58. doi: 10.1111/all.12329. Epub 2013 Nov 28.

24.

Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y, Gregoire C, Walton RP, Pearson RM, Kebadze T, Burdin N, Bartlett NW, Almond JW, Johnston SL.

PLoS Pathog. 2013;9(9):e1003669. doi: 10.1371/journal.ppat.1003669. Epub 2013 Sep 26.

25.

An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.

Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J, Dymond M, McLean GR, Walton RP, Glanville N, Humbles A, Khaitov M, Wells T, Kolbeck R, Leishman AJ, Sleeman MA, Bartlett NW, Johnston SL.

PLoS Pathog. 2013;9(8):e1003520. doi: 10.1371/journal.ppat.1003520. Epub 2013 Aug 1.

26.

γδT cells suppress inflammation and disease during rhinovirus-induced asthma exacerbations.

Glanville N, Message SD, Walton RP, Pearson RM, Parker HL, Laza-Stanca V, Mallia P, Kebadze T, Contoli M, Kon OM, Papi A, Stanciu LA, Johnston SL, Bartlett NW.

Mucosal Immunol. 2013 Nov;6(6):1091-100. doi: 10.1038/mi.2013.3. Epub 2013 Feb 6.

27.

The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.

Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, Carpenter H, Don AS, Morris JC, Zimmermann N, Bartlett NW, Rothenberg ME, Johnston SL, Foster PS, Mattes J.

Nat Med. 2013 Feb;19(2):232-7. doi: 10.1038/nm.3049. Epub 2013 Jan 20.

PMID:
23334847
28.

Defining critical roles for NF-κB p65 and type I interferon in innate immunity to rhinovirus.

Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, Clarke DL, Message SD, Aniscenko J, Kebadze T, Zhu J, Mallia P, Mizgerd JP, Belvisi M, Papi A, Kotenko SV, Johnston SL, Edwards MR.

EMBO Mol Med. 2012 Dec;4(12):1244-60. doi: 10.1002/emmm.201201650. Epub 2012 Nov 14.

29.

Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1.

McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL.

Antiviral Res. 2012 Sep;95(3):193-201. doi: 10.1016/j.antiviral.2012.06.006. Epub 2012 Jun 26. Erratum in: Antiviral Res. 2013 Mar;97(3):381. Peel, Tamlyn J [added].

PMID:
22742898
30.

The microbiology of asthma.

Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL.

Nat Rev Microbiol. 2012 Jun 6;10(7):459-71. doi: 10.1038/nrmicro2801. Review.

PMID:
22669219
31.

Rhinovirus infection induces expression of airway remodelling factors in vitro and in vivo.

Kuo C, Lim S, King NJ, Bartlett NW, Walton RP, Zhu J, Glanville N, Aniscenko J, Johnston SL, Burgess JK, Black JL, Oliver BG.

Respirology. 2011 Feb;16(2):367-77. doi: 10.1111/j.1440-1843.2010.01918.x. Erratum in: Respirology. 2012 Jan;17(1):192.

PMID:
21199160
32.

RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity.

Telcian AG, Laza-Stanca V, Edwards MR, Harker JA, Wang H, Bartlett NW, Mallia P, Zdrenghea MT, Kebadze T, Coyle AJ, Openshaw PJ, Stanciu LA, Johnston SL.

J Infect Dis. 2011 Jan 1;203(1):85-94. doi: 10.1093/infdis/jiq020. Erratum in: J Infect Dis. 2012 Apr;205(7):1180.

33.

Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium.

Slater L, Bartlett NW, Haas JJ, Zhu J, Message SD, Walton RP, Sykes A, Dahdaleh S, Clarke DL, Belvisi MG, Kon OM, Fujita T, Jeffery PK, Johnston SL, Edwards MR.

PLoS Pathog. 2010 Nov 4;6(11):e1001178. doi: 10.1371/journal.ppat.1001178. Erratum in: PLoS Pathog. 2012 Apr;8(4): doi/10.1371/annotation/c3f58c59-a42f-495b-a4f2-d74d55d72166.

34.

Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways.

Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebadze T, Caramori G, Zhu J, Edbrooke MR, Stanciu LA, Kon OM, Papi A, Jeffery PK, Edwards MR, Johnston SL.

Eur Respir J. 2010 Dec;36(6):1425-35. doi: 10.1183/09031936.00026910. Epub 2010 Jun 4. Erratum in: Eur Respir J. 2012 Mar;39(3):793.

35.

Genetics and epidemiology: asthma and infection.

Bartlett NW, McLean GR, Chang YS, Johnston SL.

Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):395-400. doi: 10.1097/ACI.0b013e32833066fa. Review.

PMID:
19644362
36.

Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.

Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL.

Pharmacol Ther. 2009 Jan;121(1):1-13. doi: 10.1016/j.pharmthera.2008.09.003. Epub 2008 Oct 6. Review.

PMID:
18950657
37.

Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection.

Jacobs N, Bartlett NW, Clark RH, Smith GL.

J Gen Virol. 2008 Nov;89(Pt 11):2877-81. doi: 10.1099/vir.0.2008/004119-0.

38.

Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation.

Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze J, Guy B, Almond JW, Jeffery PK, Lloyd CM, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, Johnston SL.

Nat Med. 2008 Feb;14(2):199-204. doi: 10.1038/nm1713. Epub 2008 Feb 3.

39.

Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.

Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, Stuart DI, Grimes JM, Smith GL.

J Gen Virol. 2007 Jun;88(Pt 6):1656-66.

40.

Role of deficient type III interferon-lambda production in asthma exacerbations.

Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL.

Nat Med. 2006 Sep;12(9):1023-6. Epub 2006 Aug 13.

PMID:
16906156
41.

Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.

Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL.

J Gen Virol. 2006 Jan;87(Pt 1):29-38.

PMID:
16361415
42.

Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model.

Bartlett NW, Buttigieg K, Kotenko SV, Smith GL.

J Gen Virol. 2005 Jun;86(Pt 6):1589-96.

PMID:
15914836
43.

Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence.

Stack J, Haga IR, Schröder M, Bartlett NW, Maloney G, Reading PC, Fitzgerald KA, Smith GL, Bowie AG.

J Exp Med. 2005 Mar 21;201(6):1007-18. Epub 2005 Mar 14.

44.

A new member of the interleukin 10-related cytokine family encoded by a poxvirus.

Bartlett NW, Dumoutier L, Renauld JC, Kotenko SV, McVey CE, Lee HJ, Smith GL.

J Gen Virol. 2004 Jun;85(Pt 6):1401-12.

PMID:
15166422
45.

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense.

Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW, Smith GL, Bowie A, O'Neill LA.

J Exp Med. 2003 Feb 3;197(3):343-51.

46.

Chronic disease mortality in Maine: assessing the targets for prevention.

Carvette ME, Hayes EB, Schwartz RH, Bogdan GF, Bartlett NW, Graham LB.

J Public Health Manag Pract. 1996 Summer;2(3):25-31.

PMID:
10186676

Supplemental Content

Loading ...
Support Center